NEW YORK – Kiffik Biomedical and Rubix LS said Thursday that they are partnering on the development of a rapid at-home colorectal cancer test.
The firms said that the test will combine Kiffik's interstitial fluid biomarker collection technology with Rubix LS's aptamer detection platform. The companies said that they are developing a test that uses a simple, noninvasive sample collection method and that could increase participation in colorectal cancer screening.
Financial and other terms of the agreement were not disclosed.
Lawrence, Massachusetts-based Rubix LS is a developer of aptamer-based biosensing technologies and precision diagnostics, and the collaboration will leverage its experience in the development of highly targeted molecular detection systems, the companies said. Providence, Rhode Island-based Kiffik said on its website that its Kiffik Lab interstitial fluid collection device is attached to skin, and it uses electroporation and negative pressure to extract a sample.
Kiffik Biomedical CEO George Cagna said in a statement that the companies are creating a fast, painless test that will be more accessible than current screening options.
The companies also said that they will explore the use of the combined testing technologies for other cancers and chronic diseases.